Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Assets (2021 - 2026)
Shuttle Pharmaceuticals Holdings' (SHPH) quarterly Non-Current Assets came in at $9.3 million in Q1 2026, up 2564.36% year-on-year from $350793.0 in Q1 2025, and down 6.28% quarter-over-quarter from $10.0 million in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Non-Current Assets (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Non-Current Assets history runs 6 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 2564.36% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $19.9 million, a 1448.07% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 3276.43% from the prior year.
- Non-Current Assets slipped to $9.3 million in Q1 2026 per SHPH's latest filing, from $10.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.0 million in Q4 2025 and bottomed at $64616.0 in Q1 2023.
- The 5-year median for Non-Current Assets is $327665.0 (2024), against an average of $1.5 million.
- Across the five-year window, Non-Current Assets slumped 47.06% in 2022 and surged 3276.43% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $75194.0 in 2022, then soared by 377.07% to $358731.0 in 2023, then decreased by 17.66% to $295373.0 in 2024, then jumped by 3276.43% to $10.0 million in 2025, then decreased by 6.28% to $9.3 million in 2026.
- Per Business Quant, the three latest SHPH Non-Current Assets figures stand at $9.3 million (Q1 2026), $10.0 million (Q4 2025), and $277014.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Shuttle Pharmaceuticals Holdings | 120,186.04 | 120,186.04 | - | 9.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.35 Mn |
| Dec 31, 2025 | 9.97 Mn |
| Sep 30, 2025 | 277,014.00 |
| Jun 30, 2025 | 312,512.00 |
| Mar 31, 2025 | 350,793.00 |
| Dec 31, 2024 | 295,373.00 |
| Sep 30, 2024 | 312,217.00 |
| Jun 30, 2024 | 327,665.00 |
| Mar 31, 2024 | 342,902.00 |
| Dec 31, 2023 | 358,731.00 |
| Sep 30, 2023 | 380,210.00 |
| Jun 30, 2023 | 393,759.00 |
| Mar 31, 2023 | 64,616.00 |
| Dec 31, 2022 | 75,194.00 |
| Sep 30, 2022 | 92,530.00 |
| Dec 31, 2021 | 142,026.00 |